Clinical Trials
58 trialsStudy of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono
ADePT
Trogenix ltd
EF-41
NovoCure Ltd.
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
BRIDGES
GT Medical Technologies, Inc.
FRONTIER
Boston Scientific Corporation
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
SONOBIRD
CarThera
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Beijing Biotech
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
STAR-GBM
Myosin Therapeutics Inc.
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
SELECT-2CAR
Beijing Biotech
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Alpha Tau Medical LTD.
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Jecho Biopharmaceuticals Co., Ltd.
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
DUAL-CAR-NK-GB
Beijing Biotech
ADVICE
Filamon LTD
SIGMA
Nuvation Bio Inc.
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
IPAX-2
Telix Pharmaceuticals (Innovations) Pty Limited
CCANED-CIPHER
Dysplasia Diagnostics Limited
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
VARTUTRACE
Var2 Pharmaceuticals
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics, Inc.
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
OMX-EFS-01
BioTex, Inc.
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
SPARTA
Apollomics Inc.
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals LLC
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
TIGER France
NovoCure Ltd.
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Kian Immune Cell Company